ECSP12011992A - Formulación de liberación sostenida - Google Patents

Formulación de liberación sostenida

Info

Publication number
ECSP12011992A
ECSP12011992A ECSP12011992A ECSP12011992A EC SP12011992 A ECSP12011992 A EC SP12011992A EC SP12011992 A ECSP12011992 A EC SP12011992A EC SP12011992 A ECSP12011992 A EC SP12011992A
Authority
EC
Ecuador
Prior art keywords
sustained release
release formulation
salt
present
compound
Prior art date
Application number
Other languages
English (en)
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of ECSP12011992A publication Critical patent/ECSP12011992A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a una formulación de liberación sostenida que comprende un derivado de metastina y un copolímero de ácido láctico-ácido glicólico que tiene un peso molecular peso promedio de aproximadamente 5.000 a aproximadamente 40.000 o una sal del mismo. La formulación de liberación sostenida de la presente invención libera en forma lenta y estable el compuesto (I) o una sal del mismo durante mucho tiempo y ejerce un efecto medicinal del compuesto (I) o una sal del mismo durante un período de tiempo extenso. Además, la formulación de liberación sostenida de la presente invención, que mejora la conveniencia del paciente reduciendo el número de episodios de administración, es una excelente formulación como una medicina clínica.
ECSP12011992 2009-12-22 2012-06-21 Formulación de liberación sostenida ECSP12011992A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2009290364 2009-12-22
JP2010144793 2010-06-25

Publications (1)

Publication Number Publication Date
ECSP12011992A true ECSP12011992A (es) 2012-07-31

Family

ID=43743497

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP12011992 ECSP12011992A (es) 2009-12-22 2012-06-21 Formulación de liberación sostenida

Country Status (26)

Country Link
US (2) US20120302508A1 (es)
EP (1) EP2515878B1 (es)
JP (3) JP2013514968A (es)
KR (1) KR20120098906A (es)
CN (2) CN102665690A (es)
AR (1) AR079657A1 (es)
AU (1) AU2010336168A1 (es)
BR (1) BR112012014947A2 (es)
CA (1) CA2785021C (es)
CO (1) CO6551752A2 (es)
CR (1) CR20120290A (es)
DO (1) DOP2012000171A (es)
EA (1) EA020865B1 (es)
EC (1) ECSP12011992A (es)
ES (1) ES2434315T3 (es)
IL (1) IL219967A0 (es)
MA (1) MA33910B1 (es)
MX (1) MX2012006441A (es)
NZ (1) NZ600157A (es)
PE (1) PE20121481A1 (es)
SG (1) SG181436A1 (es)
TN (1) TN2012000255A1 (es)
TW (1) TW201125575A (es)
UY (1) UY33127A (es)
WO (1) WO2011078394A2 (es)
ZA (1) ZA201203775B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2585091B1 (en) * 2010-06-25 2014-09-10 Takeda Pharmaceutical Company Limited Sustained-release formulation comprising a metastin derivative
WO2016020901A1 (en) 2014-08-07 2016-02-11 Acerta Pharma B.V. Methods of treating cancers, immune and autoimmune diseases, and inflammatory diseases based on btk occupancy and btk resynthesis rate
IL311335A (en) 2016-09-30 2024-05-01 Sumitomo Pharma Switzerland Gmbh Methods for treating female infertility

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9211268D0 (en) * 1992-05-28 1992-07-15 Ici Plc Salts of basic peptides with carboxyterminated polyesters
FR2693905B1 (fr) * 1992-07-27 1994-09-02 Rhone Merieux Procédé de préparation de microsphères pour la libération prolongée de l'hormone LHRH et ses analogues, microsphères et formulations obtenues.
WO2001078687A1 (en) * 2000-04-18 2001-10-25 Peptron Inc. Injectable sustained release pharmaceutical composition and processes for preparing the same
AR023940A1 (es) * 2000-05-03 2002-09-04 Eriochem Sa Procedimiento para la produccion de microcapsulas de liberacion prolongada de peptidos solubles en agua
EP1317304B1 (en) * 2000-09-01 2011-04-27 Palmaya Pty Ltd. Slow release pharmaceutical preparation and method of administering same
WO2002043709A1 (fr) * 2000-12-01 2002-06-06 Takeda Chemical Industries, Ltd. Procede de production d'une preparation contenant une substance bioactive
JP2003002841A (ja) * 2001-04-20 2003-01-08 Takeda Chem Ind Ltd ペプチド含有製剤
WO2002085399A1 (en) * 2001-04-20 2002-10-31 Takeda Chemical Industries, Ltd. Peptide-containing preparations
KR20050090420A (ko) * 2002-12-26 2005-09-13 다케다 야쿠힌 고교 가부시키가이샤 메타스틴 유도체 및 이의 용도
SG153865A1 (en) 2004-06-25 2009-07-29 Takeda Pharmaceutical Metastin derivatives and use thereof
TW200613012A (en) * 2004-07-02 2006-05-01 Takeda Pharmaceuticals Co Sustained-release composition, process for producing the same and use of the same
CN1923284A (zh) * 2005-08-30 2007-03-07 孔庆忠 抗癌药物缓释注射剂及其应用
UA97236C2 (en) * 2005-12-22 2012-01-25 Такеда Фармасьютикал Компани Лимитед Metastin derivatives and use thereof
US8404643B2 (en) * 2005-12-22 2013-03-26 Takeda Pharmaceutical Company Limited Metastin derivatives and use thereof
TWI386417B (zh) * 2005-12-22 2013-02-21 Takeda Pharmaceutical 轉移抑素衍生物及其用途
KR101522035B1 (ko) * 2006-12-18 2015-05-20 다케다 야쿠힌 고교 가부시키가이샤 서방성 조성물 및 이의 제조 방법
JPWO2009131191A1 (ja) * 2008-04-24 2011-08-25 武田薬品工業株式会社 メタスチン誘導体およびその用途
PE20110939A1 (es) * 2008-12-29 2012-01-19 Takeda Pharmaceutical Agente preventivo/terapeutico contra el cancer
RU2582678C2 (ru) * 2010-08-13 2016-04-27 Эйлерон Терапьютикс, Инк. Пептидомиметические макроциклы

Also Published As

Publication number Publication date
NZ600157A (en) 2013-07-26
WO2011078394A3 (en) 2012-03-15
BR112012014947A2 (pt) 2019-09-24
ZA201203775B (en) 2013-08-28
MA33910B1 (fr) 2013-01-02
JP6472730B2 (ja) 2019-02-20
AU2010336168A1 (en) 2012-06-14
IL219967A0 (en) 2012-07-31
SG181436A1 (en) 2012-07-30
DOP2012000171A (es) 2012-08-31
UY33127A (es) 2011-07-29
JP2013514968A (ja) 2013-05-02
US20120302508A1 (en) 2012-11-29
PE20121481A1 (es) 2012-11-12
EP2515878A2 (en) 2012-10-31
WO2011078394A2 (en) 2011-06-30
AR079657A1 (es) 2012-02-08
CR20120290A (es) 2012-09-06
CA2785021C (en) 2019-03-05
JP2016029045A (ja) 2016-03-03
EP2515878B1 (en) 2013-10-30
CN107412725A (zh) 2017-12-01
CO6551752A2 (es) 2012-10-31
ES2434315T3 (es) 2013-12-16
CN102665690A (zh) 2012-09-12
TW201125575A (en) 2011-08-01
KR20120098906A (ko) 2012-09-05
JP2017160201A (ja) 2017-09-14
CA2785021A1 (en) 2011-06-30
US20180228732A1 (en) 2018-08-16
TN2012000255A1 (en) 2013-12-12
EA020865B1 (ru) 2015-02-27
EA201290372A1 (ru) 2012-12-28
MX2012006441A (es) 2012-06-28

Similar Documents

Publication Publication Date Title
CY1122516T1 (el) Ετοιμες προς χρηση διατυπωσεις κετορολακης
BR112013027674A2 (pt) "usos de composições de nanopartículas, composições compreendendo as referidas nanopartículas e cateter com uma agulha".
NI201200089A (es) INHIBIDORES DE N1 - PIRAZOLOESPIROCETONA ACETIL - CoA CARBOXILASA.
BR112014029208A2 (pt) formulação para implante de paliperidona
ECSP15039103A (es) Formulación de liberación sostenida de mosapride que proporciona efectos farmacológicos y clínicos con administración una vez al día
DOP2011000343A (es) Derivados de piridina tieno [2,3-b] como inhibidores de replicacion viral
BR112014029209A2 (pt) formulação para implante de risperidona ou paliperidona
DOP2012000011A (es) Formulacion farmaceutica
CO6640206A2 (es) Formulación farmaceútica de una solución acuosa de un bufer de ácido glutámico y un anticuerpo
CR20110568A (es) Guía con sensor
GT201000182A (es) Regimen de dosificacion asociado con ésteres de paliperidona inyectables de acción prolongada
BRPI1002601E2 (pt) composição nanoestruturada de uso veterinário para administração de fármacos
BR112013022495A2 (pt) formulação farmacêutica aquosa de tapentadol para administração oral
GT201400069A (es) Composiciones farmaceuticas
DOP2013000243A (es) Inhibidores sustituidos de acetil-coa carboxilasa
BR112013016770A2 (pt) formulação farmacêutica, fármaco biofarmacêutico, seringa ou caneta pré-preenchida, uso de uma formulação farmacêutica
CU23814A3 (es) Emulsión intravenosa de butilftalida y aplicación de la misma
JP2012517449A5 (es)
AR069674A1 (es) Nanoparticulas que contienen farmaco
AR077125A1 (es) Combinaciones farmaceuticas utiles para tratar el vhc
CO6331308A2 (es) Derivados de carboxamidaindazol con actividad sobre el receptor cb1 y composiciones farmaceuticas que los comprenden
AR077138A1 (es) Composiciones farmaceuticas utiles para tratar el vhc
BR112015014433A2 (pt) compostos tricíclicos
ECSP12011992A (es) Formulación de liberación sostenida
DOP2012000304A (es) Formulacion de liberacion sostenida